Genomics

22 posts

John Theurer Cancer Center/RCCA collaborate with GTC to internalize proprietary NGS DNA and RNA testing

John Theurer Cancer Center and GTC

John Theurer Cancer Center to Establish Next Generation Sequencing Laboratory for Precision Genomic Profiling of Cancers, Adapting Testing Developed for DNA and RNA IRVINE, Calif. and Hackensack, NJ, [May 27th, 2020] John Theurer Cancer Center (JTCC), at Hackensack Meridian Health Hackensack University Medical Center in New Jersey, and Genomic Testing Cooperative (GTC), Irvine, CA, announced […]

Read More

Do not Accept partial results about PH-Like Acute Lymphoblastic Leukemia

DNA RNA ALL

Distinguishing PH-like acute lymphoblastic leukemia (ALL) from other types of ALL relies on full evaluation of the molecular abnormalities in the leukemic cells. Order GTC Hematology Molecular Profile Plus GTC Hematology Profile Plus and obtain complete evaluation of mutations in DNA of 177 genes and fusion/expression/mutations in RNA of 1408 genes. Here is an example […]

Read More

Time Matters on Health Tests [TAT-NGS]

Turn Around Time, Turnaround Time, TAT, NGS (Next Generation Sequencing), Next-Gen, NGS, TTI (Time to Treatment Initiation), GTC

We’re always competing with ourselves on improving turn around time (TAT) because we know patients depend on the results Most studies suggest that treatment delay leads to a worse outcome Patients with cancer who have to wait longer for treatment suffer from significant anxiety and stress Physicians and patients deserve to get the results of […]

Read More

Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Order GTC Hematology Expression/Fusion Profile   The GTC Hematology Expression/Fusion test provides actionable information for: 1) Determining Fusion and classification (Ph-Positive or Ph-Like) Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with genomic alterations dominated by structural chromosomal abnormalities, particularly translocations. Most of the reported chromosomal translocations in ALL lead to the expression of fusion […]

Read More

23rd Annual International Congress on Hematologic Malignancies 2019

Dr. Maher Albitar at the 23rd Annual International Congress on Hematologic Malignancies 2019

23rd Annual International Congress on Hematologic Malignancies 2019: Focus on Leukemias, Lymphomas and Myeloma   The annual International Congress on Hematologic Malignancies is dedicated to providing clinicians access to emerging data in treating hematologic malignancies. Providing practical tools to optimize therapy and personalize care. Our Chief Medical Officer Dr. Maher Albitar will be presenting Beyond […]

Read More

Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma

Order GTC Hematology Expression/Fusion Profile GTC Hematology Expression/Fusion Profiling provides highly informative and actionable data for patients with DLBCL as follows: 1) B-cell Markers: This assay provides data on the expression of markers specific to B-cell. It will report the levels of expression of B-cell markers, including CD19, CD79A, CD79B, PAX5, CD22, and others. The […]

Read More

Sarcoma Diagnosis and Classification

Sarcoma Diagnosis and Classification

Order GTC Solid Tumor Expression/Fusion Profile Sarcoma Diagnosis and Classification. The GTC Solid Tumor Expression/Fusion Profiling provides highly informative and actionable data for patients with sarcoma. Sarcomas are heterogeneous group of cancer that arises in the connective tissue. Diagnosis and subclassification of sarcoma can be very difficult due to overlapping in histological and immunohistological features. […]

Read More